W. Marston Linehan
National Institutes of Health
632 Papers
4.6K Citations
W. Marston Linehan is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Medicine & Renal cell carcinoma. The author has an hindex of 112, co-authored 568 publications. Previous affiliations of W. Marston Linehan include Armed Forces Institute of Pathology & Science Applications International Corporation.
Chat about Author
Papers
Clinical Utility of Functional Imaging with 18F-FDOPA in Von Hippel-Lindau Syndrome
Allison B. Weisbrod,Mio Kitano,Krisana Gesuwan,Corina Millo,Peter Herscovitch,Naris Nilubol,W. Marston Linehan,Electron Kebebew +7 more
TL;DR: ¹⁸F-FDOPA PET is a useful complementary imaging study to detect neuroendocrine tumors in patients with VHL undergoing surveillance, especially in those suspected to have adrenal pheochromocytoma or unusual ectopic locations.
Molecular cloning of the von hippel-lindau tumor suppressor gene and its role in renal carcinoma
James R. Gnarra,D. Roxanne Duan,Yongkai Weng,Jeffrey S. Humphrey,David Y. T. Chen,Stephen S. Lee,Arnim Pause,Claire F. Dudley,Farida Latif,Igor Kuzmin,Laura S. Schmidt,Fuh Mei Duh,Thomas Stackhouse,F. Chen,Takeshi Kishida,Ming Hui Wei,Michael I. Lerman,Berton Zbar,Richard D. Klausner,W. Marston Linehan +19 more
Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer
William L. Dahut,James L. Gulley,Philip M. Arlen,Yinong Liu,Katherine M. Fedenko,Seth M. Steinberg,John J. Wright,Howard L. Parnes,Clara C. Chen,Elizabeth C. Jones,Catherine Parker,W. Marston Linehan,William D. Figg +12 more
TL;DR: The addition of thalidomide to docetaxel resulted in an encouraging PSA decline rate and overall median survival rate in patients with metastatic AIPC, and the combination regimen was well tolerated.
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Lee E. Moore,Michael L. Nickerson,Paul Brennan,Jorge R. Toro,Erich Jaeger,Jessica Rinsky,Summer S. Han,David Zaridze,Vsevolod Matveev,Vladimir Janout,H. Kollarova,Vladimir Bencko,Marie Navratilova,Neonilia Szeszenia-Dabrowska,Dana Mates,Laura S. Schmidt,Laura S. Schmidt,Petra Lenz,Sara Karami,W. Marston Linehan,Maria J. Merino,Stephen J. Chanock,Paolo Boffetta,Paolo Boffetta,Wong Ho Chow,Frederic M. Waldman,Nathaniel Rothman +26 more
TL;DR: In this article, a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL-inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs) was provided.
Robotic Partial Nephrectomy for Renal Hilar Tumors: A Multi-Institutional Analysis
C. Rogers,C. Rogers,Adam R. Metwalli,Adam M. Blatt,Gennady Bratslavsky,Mani Menon,W. Marston Linehan,Peter A. Pinto +7 more
TL;DR: Robotic assistance may facilitate tumor resection and renal reconstruction for challenging renal hilar tumors, offering a minimally invasive and nephron sparing surgical option for select patients who might otherwise require open surgery or total nephrectomy.